Jefferies keeps EUR 16.00 target for Almirall stock

Published on 10/17/2026 at 19:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall reports results on November 9, 2026. Almirall stock costs EUR 10.02 on October 16, 2026, down 0.99 percent versus the prior close.

Targets and reporting dates

Jefferies maintained its EUR 16.00 target for Almirall on October 8, 2026.
Almirall is scheduled to report nine-month 2026 results on November 9, 2026.
Almirall stock was last at EUR 10.02 on October 16, 2026 at 5:35 p.m. CEST, down 0.99 percent versus the prior BME close of EUR 10.12.
Almirall had a EUR 2.2 billion market capitalization and a P/E ratio of 30.24.

Aquarellmalerei der Barcelona-Skyline mit modernen Bürotürmen im Mittelmeerlicht — Almirall S.A. (ES0157097017) präsentiert die Barcelona-Skyline als Aquarell, Heimatstadt des IBEX-35-Pharmaunternehmens Almirall, Illustration mit AI erstellt.

Jefferies maintained a EUR 16.00 price target for Almirall on October 8, 2026, putting the target 59.68 percent above the stock's EUR 10.02 last price. Estrategias de Inversion reported the target and reiterated Jefferies' positive view. Almirall was last at EUR 10.02 on October 16, 2026 at 5:35 p.m. CEST, down 0.99 percent versus the prior BME close of EUR 10.12.

November date sets the next checkpoint

Almirall's investor calendar lists November 9, 2026 for its nine-month 2026 financial results. The company also lists February 22, 2027 for full-year 2026 results, giving investors two dated checkpoints for the operating picture. Almirall identifies both dates on its investor page.

Price position on the BME

The October 16 price stood 1.93 percent above the 52-week low of EUR 9.81 and 28.33 percent below the 52-week high of EUR 13.98. Trading volume was 129,596 shares, compared with an average volume of 130,524 shares. The narrow gap between those volume figures places the session close to Almirall's recent trading pattern.

Valuation and reporting date

Almirall's market capitalization was EUR 2.2 billion, while its price-to-earnings ratio was 30.24. Those figures put the stock's valuation alongside the upcoming November reporting date rather than a new company announcement. Almirall's specialty pharmaceutical profile remains centered on medical dermatology, with the BME listing providing the relevant home-market reference.

Comparison with peers

Almirall (BME, EUR): minus 0.99 percent, P/E 30.24, market capitalization EUR 2.2 billion.

Laboratorios Rovi (BME, EUR): plus 1.20 percent, P/E 16.10, market capitalization EUR 3.0 billion.

Pharma Mar (BME, EUR): minus 0.74 percent, P/E 20.81, market capitalization EUR 1.2 billion.

What the target gap means

The EUR 16.00 target is 59.68 percent above the EUR 10.02 price, calculated in the same currency. The gap is a measurable valuation reference, while the next company-specific date is November 9, 2026. The price position remains separate from that analyst assessment and is stated only through the dated BME quotation.